SCHEMBL144074

SCHEMBL144074

NC(=O)c1cc(Br)cc2c1[nH]c1cc(NC(=O)O)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 12/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
IKBKB O14920 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPK10 P53779 1/20 0.44
HSD17B10 Q99714 1/20 0.44
JAK1 P23458 5/20 0.43
TYK2 P29597 5/20 0.43
JAK3 P52333 5/20 0.43
KIF11 P52732 3/20 0.41
BTK Q06187 3/20 0.39
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146471 0.83 JAK2 (0.66) JAK2MEN1KMT2AIKBKBUSP2
SCHEMBL27998034 0.82 JAK2 (0.47) JAK2MEN1KMT2AALOX15MAPK1
SCHEMBL141907 0.81 JAK2 (0.56) JAK2MEN1KMT2AIKBKBUSP2
SCHEMBL143095 0.80 MEN1 (0.49) JAK2MEN1KMT2AIKBKBUSP2
SCHEMBL140996 0.79 MEN1 (0.48) JAK2MEN1KMT2AIKBKBUSP2
SCHEMBL27852013 0.78 JAK2 (0.55) JAK2MEN1KMT2AIKBKBUSP2
SCHEMBL15789633 0.75 JAK2 (0.78) JAK2JAK1TYK2JAK3BTK
SCHEMBL15995494 0.75 KIF11 (0.39) KMT2AALDH1A1KIF11KDM4E
SCHEMBL143497 0.75 BTK (0.50) MEN1KMT2AIKBKBUSP2ALDH1A1
SCHEMBL141460 0.74 JAK2 (0.50) JAK2MEN1KMT2AIKBKBUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885MEN1 2279/4885KMT2A 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.